China's Hansoh Pharma H1 revenue rises, driven by innovative medicines segment

Hansoh Pharmaceutical

26/08/2026 10:33

Overview
China pharmaceutical firm's H1 revenue rose 11.7% yr/yr, driven by innovative medicines segment
Net profit for the period increased 35.8%
Profit growth attributed to higher innovative medicine revenue and increased other income

Outlook
Company did not provide specific financial guidance for the current qtr or full yr in the press release

Result Drivers
INNOVATIVE MEDICINES - Co said increased revenue from innovative medicines was the main driver of profit and EPS growth
PRODUCT INDICATION EXPANSION - Expanded indications and approvals for Ameile and other products contributed to revenue growth
R+D INVESTMENT - Increased R+D spending supported new product development and pipeline expansion

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 8.3 bln
 
H1 Net Income Attributable
 
RMB 4.26 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Hansoh Pharmaceutical Group Company Limited is HK$44.68, about 40.8% above its August 26 closing price of HK$31.74
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 32 three months ago

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-26/cc5c04b1-8f7d-4486-a470-79782c1dee2a.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)